Sphingosine kinase 1 Isoform-Specific interactions in breast cancer

Molecular Endocrinology

Volumn 28, Issue 11, 2014, Pages 1899-1915

  Yagoub, Daniel ^a,b   Wilkins, Marc R ^a   Lay, Angelina J ^b   Kaczorowski, Dominik C ^b   Hatoum, Diana ^c   Bajan, Sarah ^c   Hutvagner, Gyorgy ^c   Lai, Jack H ^d   Wu, Wengen ^d   Martiniello Wilks, Rosetta ^c   Xia, Pu ^b,e   McGowan, Eileen M ^b,c,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Centenary Institute   (United States)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e FUDAN UNIVERSITY   (China)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; DIPEPTIDYL PEPTIDASE; DREBRIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MARCKS PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; SPHINGOSINE KINASE 1; STABLE ISOTOPE; AIF1 PROTEIN, HUMAN; DIPEPTIDYL PEPTIDASE II; DNA BINDING PROTEIN; ISOPROTEIN; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENICITY; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MCF 7 CELL LINE; PROTEIN INTERACTION; PROTEIN PURIFICATION; QUANTITATIVE STUDY; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL MOTION; FEMALE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DNA-BINDING PROTEINS; FEMALE; HUMANS; LATENT TGF-BETA BINDING PROTEINS; LYSOPHOSPHOLIPIDS; MCF-7 CELLS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84908333791     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2013-1423     Document Type: Article

References (94)

1. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139-150.
2. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993;365:557-560.
3. Van Brocklyn JR, Lee M-J, Menzeleev R, et al. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol. 1998;142:229-240.
4. Spiegel S, Shida D, Takabe K, Kapitonov D, Milstien S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008; 9:662-673.
5. Leung BP, Lai WQ, Wong WSF. Sphingosine kinase and sphin-gosine 1-phosphate in asthma. Biosci Rep. 2011;31:145-150.
6. Pitson SM, Pitman MR. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets. 2010;10: 354-367.
7. Martin JL, Lin MZ, McGowan EM, Baxter RC. Potentiation of growth factor signaling by insulin-like growth factor-binding pro-tein-3 in breast epithelial cells requires sphingosine kinase activity. J Biol Chem. 2009;284:25542-25552.
8. Johnson KR, Johnson KY, Crellin HG, et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. Journal of Histochemistry, Cytochemistry. 2005;53:1159-1166.
9. Kawamori T, Osta W, Johnson KR, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 2006;20:386-388.
10. Van Brocklyn JR, Jackson CA, Pearl DK, et al. Sphingosine ki-nase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J NeuropatholExp Neurol. 2005; 64:695-705.
11. Malavaud B, Pchejetski D, Mazerolles C, et al. Sphingosine ki-nase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 2010;46:3417-3424.
12. Song LB, Li W, Yu CP, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393-1399.
13. Song LB, Liu GL, Zheng HQ, et al. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer. 2010;10:467.
14. Xia P, Wang L, Gamble J., Vadas MA. Activation of sphingosine kinase by tumor necrosis factor-a inhibits apoptosis in human endothelial cells. J Biol Chem. 1999;274:34499-34505.
15. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res. 2002;281:115-127.
16. Sarkar S, Maceyka M, Hait NC, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 2005;579:5313-5317.
17. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA, Xia P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol. 2003;17:2002-2012.
18. Antoon JW, Meacham WD, Bratton MR, et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol. 2011;46:205-216.
19. Sukocheva O, Holmes A, Albanese N, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 2005;173:9.
20. Sukocheva O, Wang LJ, Verrier E, Vadas MA, Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology. 2009;150: 4484-4492.
21. Ruckhaberle E, Karn T, Denkert C, et al. Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. J Cancer Res Clin Oncol. 2013;139:1681-1689.
22. Ohotski J, Edwards J, Elsberger B, et al. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int J Cancer. 2013;132:605-616.
23. Antoon JW, Beckman BS. Sphingosine kinase: a promising cancer therapeutic target. Cancer Biol Ther. 2011;11:647-650.
24. Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Exp Biol Med (Maywood). 2012;237:832-844.
25. Pitson SM, D’Andrea RJ, Vandeleur L, et al. Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem J 2000;350(Pt 2):429-441.
26. Ota T, Suzuki Y, Nishikawa T, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004;36:40-45.
27. Fujita T, Okada T, Hayashi S, Jahangeer S, Miwa N, Nakamura S-I. S-Catenin/NPRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1. Biochem J. 2004;382:717-723.
28. Hayashi S, Okada T, Igarashi N, Fujita T, Jahangeer S, Nakamura S. Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein. J Biol Chem. 2002;277:33319-33324.
29. Lacaná E, Maceyka M, Milstien S, Spiegel S. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J Biol Chem. 2002;277:32947-32953.
30. Leclercq TM, Moretti PAB, Vadas MA, Pitson SM. Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem. 2008;283:9606-9614.
31. Sun J, Yan G, Ren A, You B, Liao JK. FHL2/SLIM3 Decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res. 2006;99:468-476.
32. Zebol JR, Hewitt NM, Moretti PAB, et al. The CCT/TRiC chaper-onin is required for maturation of sphingosine kinase 1. Int J Biochem Cell Biol. 2009;41:822-827.
33. Lim KG, Tonelli F, Berdyshev E, et al. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b. Int J Biochem Cell Biol. 2012;44:1457-1464.
34. Loveridge C, Tonelli F, Leclercq T, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem. 2010;285:38841-38852.
35. Dobreva I, Fielding A, Foster LJ, Dedhar S. Mapping the integrin-linked kinase interactome using SILAC. J Proteome Res. 2008;7: 1740-1749.
36. Ong S-E, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protocols. 2007;1:2650-2660.
37. Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H. Essential requirement for sphingosine kinase 2 in a sph-ingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem. 2007;282:15833-15842.
38. McGowan EM, Tran N, Alling N, Yagoub D, Sedger LM, Marti-niello-Wilks R. p14ARF post-transcriptional regulation of nuclear cyclin D1 in MCF-7 breast cancer cells: discrimination between a good and bad prognosis? PLoS One. 2012;7:e42246.
39. Bachovchin DA, Koblan LW, Wu W, et al. A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014;10:656-663.
40. Candiano G, Bruschi M, Musante L, et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 2004;25:1327-1333.
41. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68:850-858.
42. Gatlin CL, Kleemann GR, Hays LG, Link AJ, Yates JR. Protein identification at the low femtomole level from silver-stained gels using a new fritless electrospray interface for liquid chromatogra-phy-microspray and nanospray mass spectrometry. Anal Biochem. 1998;263:93-101.
43. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367-1372.
44. Zeeberg BR, Qin H, Narasimhan S, et al. High-Throughput GoMiner, an’industrial-strength’ integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinform. 2005;6:168.
45. Barr RK, Lynn HE, Moretti PAB, Khew-Goodall Y, Pitson SM. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J Biol Chem. 2008;283:34994-35002.
46. Pitman MR, Barr RK, Gliddon BL, Magarey AM, Moretti PAB, Pitson SM. A critical role for the protein phosphatase 2A B' a regulatory subunit in dephosphorylation of sphingosine kinase 1. Int J Biochem Cell Biol. 2011;43:342-347.
47. Heide H, Nordhues A, Drepper F, et al. Application of quantitative immunoprecipitation combined with knockdown and cross-linking to Chlamydomonas reveals the presence of vesicle-inducing protein in plastids 1 in a common complex with chloroplast HSP90C. Pro-teomics. 2009;9:3079-3089.
48. Iyer SS, Kusner DJ. Coordinate regulation of sphingosine kinase and actin dynamics. Methods Mol Biol. 2009;531:347-361.
49. Chiravuri M, Agarraberes F, Mathieu SL, Lee H, Huber BT. Vesicular localization and characterization of a novel post-proline-cleav-ing aminodipeptidase, quiescent cell proline dipeptidase. J Immunol. 2000;165:5695-5702.
50. Coutts SJ, Kelly TA, Snow RJ, et al. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem. 1996;39: 2087-2094.
51. McGowan EM, Alling N, Jackson EA, et al. Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay. PLoS One. 2011;6:e20623.
52. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003;4:R28.
53. Hla T, Lee MJ, Thangada S, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99:301-312.
54. Siow DL, Anderson CD, Berdyshev EV, Skobeleva A, Pitson SM, Wattenberg BW. Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate. J Lipid Res. 2010;51:2546-2559.
55. Young KW, Willets JM, Parkinson MJ, et al. Ca2+/calmodulin-dependent translocation of sphingosine kinase: role in plasma membrane relocation but not activation. Cell Calcium. 2003;33:119-128.
56. Sutherland CM, Moretti PA, Hewitt NM, Bagley CJ, Vadas MA, Pitson SM. The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane. J Biol Chem. 2006;281:11693-11701.
57. Pitson SM, Xia P, Leclercq TM, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 2005;201:49-54.
58. Jarman KE, Moretti PA, Zebol JR, Pitson SM. Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1.J Biol Chem. 2010;285:483-492.
59. Kusner DJ, Thompson CR, Melrose NA, Pitson SM, Obeid LM, Iyer SS. The localization and activity of sphingosine kinase 1 are coordinately regulated with actin cytoskeletal dynamics in macrophages (vol 282, pg 23147, 2007). J Biol Chem. 2008;283:5972-5972.
60. Kaibuchi K, Amano M, Nakayama M. Rho-Kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton. 2010; 67:545-554.
61. Kihara A, Anada Y, Igarashi Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, andoligomerization. JBiol Chem. 2006; 281:4532-4539.
62. Coates PJ, Hall PA. The yeast two-hybrid system for identifying protein-protein interactions. J Pathol. 2003;199:4-7.
63. Mackay JP, Sunde M, Lowry JA, Crossley M, Matthews JM. Protein interactions: is seeing believing? Trends Biochem Sci. 2007;32: 530-531.
64. Mann M, Selbach M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods. 2006;3:981-983.
65. Cleveland DW, Ling SC, Albuquerque CP, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci USA. 2010;107: 13318-13323.
66. Ge F, Li WL, Bi LJ, Tao SC, Zhang ZP, Zhang XE. Identification of Novel 14–3–3 f interacting proteins by quantitative immunoprecipitation combined with knockdown (QUICK). J Proteome Res. 2010;9:5848-5858.
67. Neubert TA, Zhang GA, Spellman DS, Skolnik EY. Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC). J Proteome Res. 2006;5:581-588.
68. Kurochkin IV, Yonemitsu N, Funahashi S, Nomura H. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. Biochem Biophys Res Commun. 2001;280:340-347.
69. Luna EJ, Fang ZY, Takizawa N, et al. The membrane-associated protein, supervillin, accelerates F-actin-dependent rapid integrin recycling and cell motility. Traffic. 2010;11:782-799.
70. Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205): a novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J Cell Biol. 1997;139:1255-1269.
71. Takizawa N, Ikebe R, Ikebe M, Luna EJ. Supervillin slows cell spreading by facilitating myosin II activation at the cell periphery. J Cell Sci. 2007;120:3792-3803.
72. Guo YR, Singleton PA, Rowshan A, et al. Quantitative proteomics analysis of human endothelial cell membrane rafts—evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol Cell Proteomics. 2007;6:689-696.
73. Chang C, Ting HJ, Yeh S, Nishimura K. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA. 2002;99:661–666.
74. Cuvillier O, Martin C, Lafosse JM, Malavaud B. Sphingosine ki-nase-1 mediates androgen-induced osteoblast cell growth. Biochem Biophys Res Commun. 2010;391:669–673.
75. Dayon A, Brizuela L, Martin C, et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. Plos One. 2009:e8048.
76. Tari AM, Hung MC, Li KY, Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 1999;18:1325–1332.
77. Pitson SM, Moretti PAB, Zebol JR, et al. Activation of sphingosine kinase1 byERK1/2-mediated phosphorylation. EMBO J.2003;22: 5491–5500.
78. Huwiler A, Doll F, Pfeilschifter J. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocr Related Cancer. 2007;14:325–335.
79. Donehower LA, Lu XB, Nguyen TA, Moon SH, Darlington Y, Sommer M. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metast Rev. 2008;27:123–135.
80. Watson C, Long JS, Orange C, et al. High expression of sphingosine 1-phosphate receptors, S1p(1) and S1p(3), sphingosine kinase 1 and Erk-1/2 is associated with development of tamoxifen resistance in Er positive breast cancer patients. EJC Suppl. 2010;8:21–21.
81. Vadas M, Xia P, McCaughan G, Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta Mol Cell Biol Lipids. 2008;1781:442–447.
82. Donowitz M, Cha BY, Zachos NC, et al. NHERF familyand NHE3 regulation. J Physiol (London). 2005;567:3–11.
83. Tornquist K, Gratschev D, Lof C, et al. Sphingosine kinase as a regulator of calcium entry through autocrine sphingosine 1-phosphate signaling in thyroid FRTL-5 cells. Endocrinology. 2009;150: 5125–5134.
84. Lof C, Tornquist K. Sphingosine kinase 1 as a regulator of calcium entry. Chem Physics Lipids. 2009;160:S31–S31.
85. Tornquist K, Blom T, Bergelin N, Slotte JP. Sphingosine kinase regulates voltage operated calcium channels in GH(4)C(1) rat pituitary cells. Cell Signal. 2006;18:1366–1375.
86. Heringdorf DMZ. Calcium mobilization by sphingosine kinase and sphingosine-1-phosphate. FEBS J. 2005;272:246–246.
87. Obeid LM, Taha TA, El-Alwani M, Hannun YA. Sphingosine ki-nase-1 is cleaved by cathepsin B in vitro: Identification of the initial cleavage sites for the protease. FEBS Lett. 2006;580:6047–6054.
88. Obeid LM, Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem. 2005;280:17196-17202.
89. Antoon JW, Meacham WD, Bratton MR, et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol. 2011;46:205-216.
90. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sph-ingosine kinase-1 signaling pathway. Endocrinology. 2009;150: 4484–4492.
91. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489–503.
92. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36(suppl 2):S245–S252.
93. Haass NK, Nassif N, McGowan EM. Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. BioMed Research International, Special Issue accepted August 2014.
94. Inagaki Y, Li PY, Wada A, Mitsutake S, Igarashi Y. Identification of functional nuclear export sequences in human sphingosine kinase 1. Biochem Biophys Res Commun. 2003;311:168–173.